MYD88 and primary central nervous system lymphoma: In contrast to our plasma analysis, studies have shown that the VAF of MYD88 L265P in the CSF of PCNSL ranges from 2.6% to more than 90%, and that positive results can be obtained in about 50% of PCNSL patients [21–23].